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Transcriptome Sequencing Demonstrates that Human
Papillomavirus Is Not Active in Cutaneous Squamous
Cell Carcinoma
Sarah T. Arron1,5, J. Graham Ruby2,3,5, Eric Dybbro1, Don Ganem3,4 and Joseph L. DeRisi2,3
b-Human papillomavirus (b-HPV) DNA is present in some cutaneous squamous cell carcinomas (cuSCCs), but
no mechanism of carcinogenesis has been determined. We used ultra-high-throughput sequencing of the
cancer transcriptome to assess whether papillomavirus transcripts are present in these cancers. In all, 67 cuSCC
samples were assayed for b-HPV DNA by PCR, and viral loads were measured with type-specific quantitative
PCR. A total of 31 SCCs were selected for whole transcriptome sequencing. Transcriptome libraries were
prepared in parallel from the HPV18-positive HeLa cervical cancer cell line and HPV16-positive primary cervical
and periungual SCCs. Of the tumors, 30% (20/67) were positive for b-HPV DNA, but there was no difference in
b-HPV viral load between tumor and normal tissue (P¼ 0.310). Immunosuppression and age were significantly
associated with higher viral load (P¼ 0.016 for immunosuppression; P¼ 0.0004 for age). Transcriptome
sequencing failed to identify papillomavirus expression in any of the skin tumors. In contrast, HPV16 and
HPV18 mRNA transcripts were readily identified in primary cervical and periungual cancers and HeLa cells.
These data demonstrate that papillomavirus mRNA expression is not a factor in the maintenance of cuSCCs.
Journal of Investigative Dermatology (2011) 131, 1745–1753; doi:10.1038/jid.2011.91; published online 14 April 2011
INTRODUCTION
Although 12% of all human cancers are now known to be
caused by viruses (Parkin, 2006; Zur Hausen, 2009), the mere
presence of viral DNA in a tumor does not necessarily
indicate causality. Multiple lines of evidence suggest a viral
etiology for cutaneous squamous cell carcinoma (cuSCC).
In immunosuppressed solid organ-transplant recipients, the
incidence of cuSCC is 65- to 250-fold higher than in the
general population (Hartevelt et al., 1990; Jensen et al., 1999;
Lindelof et al., 2000); incidence ratios of this magnitude are
commonly seen in other viral cancers, including human
herpesvirus-8-mediated Kaposi’s sarcoma and hepatitis B
virus-associated hepatocellular carcinoma (Vajdic et al.,
2006). A second line of evidence supporting viral etiology
is the behavior of the keratoacanthoma (KA) subtype of cuSCC.
KA can spontaneously regress, and has been suggested to lie
along a spectrum of carcinogenesis between hyperplastic viral
verrucae and neoplastic SCCs (LeBoit, 2002).
Previous studies have selectively focused on human
papillomavirus (HPV) as a potential etiologic agent in cuSCC.
Investigators have hypothesized an analogy between cuSCC
and cervical SCC, as the latter has been firmly associated with
high-risk a-genus HPV (a-HPV) infection, including HPV16
and HPV18 (IARC, 2007; Bouvard et al., 2009). However,
different HPV types have site-specific tropism for mucosal or
cutaneous epithelium; the high-risk mucosal a-HPVs are not
found in cuSCCs, with the exception of genital and
periungual tumors (Moy et al., 1989; Alam et al., 2003;
Dubina and Goldenberg, 2009). Thus, many studies focus on
detection of the cutaneous b-genus HPV types (b-HPV) in
cuSCCs (Shamanin et al., 1994, 1996; Surentheran et al.,
1998; Berkhout et al., 2000; Harwood et al., 2000; Forslund
et al., 2003b; Asgari et al., 2008).
The association of b-HPV with cuSCC is clearly defined for
a specific group of patients with epidermodysplasia verruci-
formis, an autosomal recessive genodermatosis associated
with susceptibility to b-HPV. Patients with epidermodysplasia
verruciformis develop widespread viral warts and b-HPV5-
and b-HPV8-mediated SCCs (Harwood et al., 1999). How-
ever, the b-HPV types have not been firmly associated with
cuSCC in the general population (IARC, 2007). b-HPV DNA
is detected in 27–54% of SCCs from immunocompetent
patients and 55–84% of SCCs from immunosuppressed
patients (Shamanin et al., 1994, 1996; Berkhout et al.,
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1995, 2000; Harwood et al., 2000; Forslund et al., 2003a,
2007; Asgari et al., 2008). Indeed, in other studies, b-HPV has
been detected with comparable frequency in normal skin,
eyebrow hairs, and premalignant actinic keratoses (Boxman
et al., 1997; Antonsson et al., 2000; Forslund et al., 2003b;
Hazard et al., 2007; de Koning et al., 2007, 2009; Asgari et al.,
2008). Other studies have reported an association between
antibody responses to b-HPV and the development of cuSCC,
particularly for patients with antibodies to multiple HPV types
(Karagas et al., 2006; Bouwes Bavinck et al., 2010).
High-risk a-HPV, which are present in over 95% of cervical
SCCs, often integrate into the human genome and express viral
proteins that interfere with normal cell cycle control (reviewed
in zur Hausen, 1996; Bosch et al., 2002). The E6 and E7
proteins of the high-risk a-HPV types interfere with the tumor-
suppressor activities of cellular p53 and retinoblastoma protein
to drive carcinogenesis (Dyson et al., 1989; Scheffner et al.,
1990; Werness et al., 1990). Ongoing expression of E6 and E7 is
required for both induction and maintenance of carcinogenesis.
By analogy, b-HPV would be expected to utilize the same
mechanism of carcinogenesis, but studies using in situ hybridi-
zation or reverse transcriptase-PCR to detect HPV mRNA in
cuSCC have detected viral transcripts only sporadically and at
low levels in occasional tumors, with many other tumors testing
negative (Purdie et al., 2005; Dang et al., 2006). Nevertheless,
many authors continue to point to b-HPV as a possible etiologic
agent in these tumors.
The goal of our study was to assess whether b-HPV is
capable of causing cuSCC through expression of viral
oncogenes using ultra-high-throughput sequencing of the
SCC transcriptome. This comprehensive, unbiased analysis of
total tumor mRNA expression revealed no HPV transcrip-
tional activity, an observation that was further supported by
the absence of a substantial viral load in the tumors. These
two observations contradict the hypothesis that transcription
of viral oncogenes is required for tumor maintenance.
RESULTS
Patient characteristics
We enrolled 38 patients, including 27 males and 11 females,
ranging in age from 41 to 95 years (Table 1). Of these
patients, 17 were immunocompetent and 21 were immuno-
suppressed because of solid organ transplantation, hemato-
logic malignancy, HIV, or medication for Wegener’s
granulomatosis. A total of 89 tissue samples were collected
from these patients, including 71 SCCs (23 KA subtype) and
18 normal skin samples. Four tumor samples did not yield
enough tissue for DNA extraction but RNA was obtained for
transcriptome analysis. Two a-HPV16-mediated primary
tumors were obtained for comparison: a periungual SCC
from a 53-year-old immunocompetent man and a stage I
nonkeratinizing cervical SCC from a 35-year-old woman. The
a-HPV18-mediated HeLa cervical cancer cell line was used
as an additional control.
Low viral load of b-HPV in normal skin and cuSCC
In all, 85 DNA samples were assayed for the presence of
b-globin DNA by PCR and all demonstrated sufficient
quantity and integrity for b-HPV typing. Of 67 cuSCC tumors,
20 (30%) were positive for HPV DNA by PCR, 18 of which
were confirmed by sequencing. Of the 18 normal skin
samples, 5 (28%) were also HPV positive by PCR and
sequence confirmation (Table 2). In all, 11 HPV types and 14
incompletely sequenced fragment types were detected, with
no single type predominating. Multivariate regression model-
ing demonstrated no difference in b-HPV carriage between
tumor and normal tissue when controlling for age, sex, and
immunosuppression as well as clustering for multiple samples
from the same patient (P¼ 0.693). Immunosuppression and
older age were significantly associated with b-HPV carriage
(P¼0.018 for both). PCR and sequencing confirmed the
presence of a-HPV16 in the primary cervical and periungual
SCCs and a-HPV18 in HeLa cells. In addition, the periungual
SCC was found to contain b-HPV8 and FA51.2 DNA.
Viral loads were determined for up to 3 HPV types in 23 of
the 24 HPV PCR-positive and sequence-confirmed samples.
Replicate assays were performed for HPV18 in the HeLa cer-
vical cancer cell line, HPV16 in the cervical SCC, and HPV16
and HPV8 in the periungual SCC (Table 2 and Figure 1a).
With the exception of four samples (one normal skin and
three tumors), all viral loads were below 1 HPV copy per cell.
In contrast, the cervical SCC contained 2.4 HPV16 copies per
Table 1. Demographics
Total Male Female
Patients 38 27 11
Immunocompetent 17 10 7
Immunosuppressed 21 17 4
Solid organ transplant 12 9 3
Hematologic malignancy 6 5 1
HIV 2 2 0
Wegener’s granulomatosis 1 1 0
Age range (years) 41–95 41–95 52–95
SCC samples (KA type) 71 (23) 45 (8) 26 (15)
Immunocompetent 30 (16) 14 (6) 16 (10)
Immunosuppressed 41 (7) 31 (2) 10 (5)
Solid organ transplant 28 19 9
Hematologic malignancy 10 9 1
HIV 2 2 0
Wegener’s granulomatosis 1 1 0
Normal skin 18 14 4
Immunocompetent 8 6 2
Immunosuppressed 10 8 2
Solid organ transplant 8 6 2
Hematologic malignancy 2 2 0
Abbreviations: KA, keratoacanthoma; SCC, squamous cell carcinoma.
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cell and the HeLa cell line contained 6.3 copies per
cell, consistent with viral integration. The periungual SCC
contained 46.9 a-HPV16 copies per cell but only 0.3 b-HPV8
copies per cell.
Random-effects interval regression modeling demon-
strated no difference in b-HPV viral load between tumor
and normal tissue when controlling for age, sex, and
immunosuppression as well as clustering for multiple samples
from the same patient (P¼ 0.310). Immunosuppression and
age were significantly associated with higher viral load
(P¼0.016 for immunosuppression; P¼0.0004 for age).
No HPV transcripts observed in cuSCC
The potential oncogenicity of HPV viruses in our samples was
assessed in terms of viral gene expression by mRNA-
transcriptome sequencing (mRNA-seq). A total of 31 cuSCC
tumors (10 KA type) were assayed by high-throughput
mRNA-seq, including 10 b-HPV DNA-positive samples with
viral loads ranging from undetectable to 13.7 copies per cell.
Parallel libraries were prepared from eight patient-paired
normal skin samples as well as the aforementioned periun-
gual SCC tumor, cervical SCC, and HeLa cell samples.
Paired-end read counts per library ranged from 1.5 million to
10.6 million reads (corresponding to sequence from 740,000
to 5.3 million complementary DNA amplicons), with a
median count of 3.5 million reads (1.8 million amplicons;
Supplementary Table S2 online). After removing sequences
with low sequence complexity or with high-quality matches
to the human genome or transcriptome, reads were queried
against a database of all fully sequenced viral genomes from
RefSeq (see Materials and Methods). Abundant HPV-match-
ing reads were detected in the HeLa cell-derived and cervical
SCC-derived data sets (0.15 and 0.02% of the total reads,
respectively Figure 1b). In both, the HPV subtype identified
was an a-HPV subtype known to drive tumorigenesis in that
sample type (HPV18 and HPV16, respectively) (IARC, 2007;
Bouvard et al., 2009). Read frequencies from two technical
replicate libraries prepared from cervical SCCs were nearly
identical (0.022 and 0.018%; Figure 1c, Supplementary
Table S1 online).
Abundant HPV16 reads were also detected in the
transcriptome of the periungual SCCs (0.06% of total reads;
Figure 1b), with no reads mapping preferentially to HPV8 or
any other HPV subtype. No potentially HPV-derived reads
were detected in 30 of the cuSCC tumors and 7 of the paired
normal skin samples (Figure 1b). One normal skin sample
that was HPV negative by genomic PCR contained two HPV-
matching reads (0.00008% of the total reads), and one skin
SCC sample contained five HPV-derived reads (0.0001% of
the total read set; this sample had no DNA for genomic PCR).
No libraries contained a higher frequency of total viral-
matching reads than the lowest HPV-derived read count
among the HPV-positive control samples (0.018%), and only
five had viral read frequencies within an order of magnitude
of that value (Supplementary File S2 online). These five
samples contained a mixture of phage sequence (likely
deriving from bacteria on the skin), human klassevirus 1
(a candidate etiological agent for diarrhea that was isolated
from human stool in our lab and is therefore a likely cross-lab
contaminant; Greninger et al., 2009), and Moloney murine
leukemia virus. A reverse transcriptase deriving from the
latter was used for library construction (see Materials and
Methods), making it a likely reagent contaminant. Although
Moloney murine leukemia virus and related viruses do have
oncogenic capabilities (Cuypers et al., 1984), the sample in
which it was detected at the highest frequency was a normal
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Figure 1. Comparison of human papillomavirus (HPV) DNA viral load and abundance of HPV-derived transcripts for established HPV-driven cancers
versus normal skin and cutaneous squamous cell carcinomas (cuSCCs). (a) HPV DNA viral loads determined by type-specific quantitative PCR. For each sample
with multiple-type infection, the sum of the type-specific viral loads is shown (for details, see Table 2.) (b) Abundance of HPV-derived transcripts determined by
mRNA-transcriptome sequencing (mRNA-seq). Reads were filtered to remove host-derived and low-complexity sequence before viral mapping (see Materials
and Methods), and HPV counts are each presented as a percentage of their total data set. The most frequently matched HPV type for the HeLa, periungual
SCC, and cervical SCC samples is indicated. Cervical cancer is presented as the union of two technical replicate data sets. (c) Congruence between HPV
genomic load (blue; presented as in a) and abundance of HPV-derived transcripts (red; presented as in b) among those control samples from which both types of
data were collected.
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skin control, not a tumor (sample ID STA01-122, Dataset C,
barcode CGT, Supplementary Table S2 and Supplementary
File S2 online).
In these 39 cases of normal skin and cuSCCs, the
frequencies of HPV reads were orders of magnitude less than
those observed for any of the bona fide HPV-driven tumors.
In control samples for which both mRNA-seq and viral
genome load data were obtained, the results obtained by
these two metrics agreed with one another and with previous
descriptions of the role of HPV as an oncogenic virus;
genomes and transcripts were both abundant in HeLa cells
and cervical SCCs and both absent in healthy skin (Figure 1c).
The similarity of HPV genome and transcriptome quantitation
between HeLa cells and cervical SCCs versus periungual
SCCs supported the role for HPV in periungual SCC
tumorigenesis, whereas the quantitative similarity between
the cuSCC versus healthy skin samples implied no role for
HPV transcription in the maintenance of those tumors.
DISCUSSION
Previous studies have proposed b-HPV as a potential
causative agent in cuSCC, citing the presence of viral DNA
in tumor tissue, but these have not definitively proved an
epidemiologic association or evaluated any particular
mechanism of transformation. We used transcriptome
sequencing to test the hypothesis that HPV is required for
the maintenance of cuSCCs through expression of viral
oncoproteins. Transcriptome sequencing revealed a com-
plete absence of HPV mRNA in these tumors, similar to
paired normal skin. This stood in stark contrast to the
abundant HPV messages detected in cervical SCC and its
derivative HeLa cell line. Our results, in fact, contradict the
hypothesis that expression of viral oncogenes is required for
maintenance of cuSCCs.
Periungual SCC represents a special site on the cutaneous
epithelium. These tumors are associated with high-risk a-HPV
(Moy et al., 1989; Alam et al., 2003; Kreuter et al., 2009),
which has been reported as episomal, and in a single case,
integrated (Sanchez-Lanier et al., 1994; Theunis et al., 1999).
In our control periungual SCC, b-HPV8 and FA51.2 DNA
were detected along with a-HPV16. This tumor contained
46.9 a-HPV16 copies per cell but only 0.3 b-HPV8 copies
per cell. HPV16 mRNA reads represented 0.06% of the
transcriptome, but no b-HPV mRNA reads were detected.
Taken together, this control specimen supports our impres-
sion of a-HPV as the driver and b-HPV as a mere passenger in
periungual SCC.
As in previous studies (Shamanin et al., 1994, 1996;
Berkhout et al., 1995, 2000; Boxman et al., 1997; Antonsson
et al., 2000; Harwood et al., 2000; Forslund et al., 2003a, b,
2007; Hazard et al., 2007; de Koning et al., 2007, 2009;
Asgari et al., 2008), b-HPV DNA was detectable by nested
PCR in 30% of SCCs, but was also found in a comparable
proportion (28%) of normal skin samples. Moreover, we
found extremely low viral loads in tumors that were positive
for the viral genome. In all but three tumor samples, the viral
load was o1 copy per cell. Importantly, the three contra-
dictory samples all came from a single renal transplant
recipient with multiple KAs of the lower leg and may reflect a
unique feature of that case. Use of PCR and sequencing
allowed identification of a broad range of HPV types,
although the detection of the multiplicity of infection may
have been limited by the number of clones sequenced.
Alternate methods for b-HPV detection such as line blots and
microarrays allow simultaneous detection of types but are
limited in the types detected. Although DNA from other HPV
types may have been present in these samples, this does not
alter the conclusion of this study. The low copy number of
b-HPV DNA, combined with the absence of virally derived
oncogenic messages, strongly suggested that b-HPV tran-
scription is not required for tumor maintenance.
Our data were consistent with previous evidence that
b-HPV merely colonizes the skin. Immunosuppression and
older age were associated with a higher prevalence and viral
load of b-HPV, consistent with previous studies (Boxman
et al., 2001; Struijk et al., 2003; de Koning et al., 2009).
These phenomena likely reflected the role of the immune
system and age-related immune senescence in controlling
epidermal colonization with HPV rather than explaining the
increased incidence of SCC in organ-transplant recipients and
older patients. The prevalence of HPV DNA in tape-stripped
biopsies is far lower than that on the surface, further
supporting a passenger role (Forslund et al., 2004). Support
for b-HPV as a passenger also comes from a study of tumors
from patients with xeroderma pigmentosum, in which
prevalence of viral carriage increases with age and is very
low in tumors from children (Luron et al., 2007). A reversed
relationship in which SCC somehow results in the presence
or increase of b-HPV DNA or antibodies is possible, although
further investigation would be required to substantiate this.
Insertional mutagenesis is another mechanism of viral
oncogenesis; this mechanism has been described for oncor-
etroviruses but not for DNA viruses. High-risk a-HPV types
can integrate into the host genome but require continual
expression of the viral E6 and E7 proteins for their oncogenic
activities (Dyson et al., 1989; Scheffner et al., 1990; Werness
et al., 1990). The recently described Merkel cell polyoma-
virus, another small DNA oncovirus, also integrates into the
host genome (Feng et al., 2008), but continued expression of
the Merkel cell polyomavirus truncated large T antigen is
similarly required for carcinogenesis (Houben et al., 2010). In
contrast, there are no reports of b-HPV integration into the
genome of cuSCC. The low viral loads of b-HPV in cuSCC
reported here further indicate that even if b-HPV had
integrated, at most only a small proportion of the genomes
within any tumor could contain integrated b-HPV, casting
doubt upon integration as a carcinogenic mechanism.
It has also been suggested that b-HPV might play a role in
induction but not maintenance of cuSCC (based on higher
viral load of HPV in precancerous actinic keratoses vs.
primary SCC, metastatic tumor, or perilesional skin; Weissen-
born et al., 2005). This may occur by interfering with cellular
DNA repair or apoptosis following UV irradiation, creating a
pool of genomically unstable cells at risk of oncogenic
transformation. Our study was not designed to address this
hypothesis. But it should be noted that such a hypothesis
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would represent a substantial departure from the role played
by a-HPV in mucosal SCC and from the carcinogenic
mechanisms known to be employed by other families of
DNA tumor viruses in general. Therefore, the most straight-
forward interpretation of our data is that the sporadic and
low-level presence of b-HPV genomic DNA in these tumors,
unaccompanied by evidence of active viral gene expression,
most likely represents colonization rather than an etiologic
association.
MATERIALS AND METHODS
Sample collection
All subjects provided informed consent according to the procedures
approved by the University of California, San Francisco Committee
on Human Research and adherent to the Declaration of Helsinki
Principles. Tumor tissue was collected from patients during the
course of biopsy or excision. All specimens were held for further
processing until final pathology confirmed a diagnosis of cuSCC.
Normal tissue was collected when surgical discard was available
from postoperative reconstruction. All tissue was snap-frozen and
stored on liquid nitrogen until nucleic acid extraction.
A primary cervical cancer specimen containing HPV16
was obtained from a commercial tissue bank (ILSBio, LLC,
Chestertown, MD).
Nucleic acid isolation
Tissue samples were minced, divided, and placed in parallel
extraction pathways. DNA was extracted using the QIAamp DNA
Mini Kit with RNase A (Qiagen, Valencia, CA) as per the
manufacturer’s protocol. RNA extractions were carried out using
the RNeasy Lipid Tissue Mini Kit with on-column RNase-free DNase
I (Qiagen) as per the manufacturer’s protocol.
HPV DNA detection using PCR
A PCR assay for b-globin DNA was performed on each sample to
control for DNA integrity and for the presence of adequate quantity
of DNA. Next, 5ml of each DNA sample (30–800 ng) was tested with
primers PCO4 and GH20 as described (Bauer et al., 1991). b-HPV
PCR was carried out using the nested primer sets FAP59-FAP64 and
FAP6085F-FAP6319R (Forslund et al., 2003a, b). For the first round
of PCR, 5ml of each DNA sample was amplified using 2mM of the
FAP59 and FAP64 primers in a 50ml reaction volume including 1
Taq Buffer, 2mM MgCl2, 0.25mM dNTPs, and 1U Taq polymerase.
The reaction was carried out under the following PCR conditions:
94 1C for 2minutes followed by 25 cycles of 94 1C for 30 seconds,
50 1C for 1minute, and 72 1C for 1minute, with a final extension
time of 7minutes at 72 1C. A 5ml aliquot of the product was removed
for a second round of amplification using the nested FAP 6085F and
FAP 6319R primer pair under the same cycling conditions. a-HPV
PCR was carried out using the nested primer sets MY09-MY11 and
GP5-GP6 as described (Manos et al., 1989; Snijders et al., 2005).
The products were visualized by agarose gel electrophoresis
and bands of expected size were isolated using the PureLink Quick
Gel Extraction Kit (Invitrogen, Carlsbad, CA) and cloned using the
TOPO TA cloning System (Invitrogen). A minimum of 12 colonies
were sequenced on the ABI 3130 l Genetic Analyzer (Applied
Biosystems, Carlsbad, CA) in order to detect potential multiple
infections.
Quantification of HPV viral load by real-time quantitative PCR
Quantitative real-time PCR was performed using the Universal Probe
Library system (Roche Applied Science, Indianapolis, IN). Primer and
probe assay combinations were individually designed for each HPV
type and for human b-2-microglobulin using the online universal
probe library Design Center software (Roche). For samples with
multiple infections, we designed discriminatory assays to measure
type-specific viral loads of as many individual types as possible
(Supplementary Table S1 online). To generate standard curves, assay-
specific PCR amplicons were separated on 4% agarose gel and purified
using the PureLink Quick Gel Extraction Kit (Invitrogen). Internal
standards were generated using 10-fold dilutions of the gel-purified
products ranging from 1,000,000 to 10 input copies.
DNA samples were assayed in 20 ml reactions with a final
concentration of 1 LightCycler 480 Probes Master mix, 400 nM of
each primer, and 200nM of the universal probe library probe. Using
the LightCycler 480 (Roche), samples were heated to 95 1C for
10minutes followed by 45 cycles of 95 1C for 10 seconds, 60 1C for
30 seconds, and 70 1C for 1 second. Data were analyzed with the
LightCycler 480 software. DNA samples and standard dilution series
were run in duplicate, and total input copy numbers were calculated
using the mean crossing point (Cp) values for each sample. Input
cellular equivalents were calculated based on two copies of b-
2-microglobulin copies per cell, and HPV viral loads were
calculated as viral copies per cell.
Statistical analysis
HPV prevalence was analyzed by logistic regression including age, sex,
immunosuppression, tissue sample type, and accounting for clustering
of multiple samples within patients. HPV viral loads were analyzed
with random-effects interval regression where the HPV copy number
was left-censored at the lower limit of detection by quantitative
PCR. For both prevalence and viral load, univariate regression was
performed before multivariate modeling. Statistical analysis was
performed using Stata 11 (StataCorp LP, College Station, TX).
mRNA-seq library preparation and analysis
Poly(A)þ RNA was isolated from 3mg of total RNA using the
Oligotex Mini kit (Qiagen) according to the manufacturer’s instruc-
tions. The resulting poly(A) RNA was then amplified using the
MessageAmp II amplified RNA Amplification Kit (Ambion, Austin,
TX) using an in vitro transcription time of 14 hours at 37 1C to
generate amplified RNA. Then, 200 ng of amplified RNA was used to
generate libraries for transcriptome sequencing using an adaptation
of the protocol previously described by Yozwiak et al. (2010). In
order to multiplex up to 16 samples within 1 sequencing library,
amplified RNA samples were randomly primed and reverse
transcribed using a primer containing a 14-bp sequence common
to the 30-end of both Illumina (San Diego, CA) adapters, a random
monomer followed by a unique 3-bp barcode, and a random
hexamer (pr1A_barcode). Second-strand synthesis was primed using
pr1A followed by PCR amplification using the 18-bp Illumina/
barcode sequence without the hexamer (pr1B_barcode) for 25
cycles. PCR products were purified using DNA Clean and
Concentrator columns (Zymo Research, Orange, CA). Next, 200 ng
of each individually barcoded sample was mixed together to
generate a library of up to 16 samples, with each sample marked
by a unique 3-bp barcode. Library purification, size selection, and
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amplification proceeded as previously described (Yozwiak et al.,
2010). Three multiplexed transcriptome libraries were analyzed on
three separate paired-end sequencing runs using the Genome
Analyzer II (Illumina) and designated Datasets A, B, and C. Barcodes
and corresponding samples are listed in Supplementary Table S2
online. Each run generated pairs of 65 nt reads. These data have been
submitted to the NCBI Sequence Read Archive under accession
number SRA029929.
Read pairs from each library were sorted by 3 nt barcode
(nucleotides 2–4 of each read), requiring that at least one of the
two reads from each pair contained a perfect match to an input
barcode and that the other contained at most one mismatch. This
yielded the ‘‘total’’ read counts shown in Supplementary Table S2
online. For analysis, we removed from each read the nucleotide
preceding the barcode, the barcode itself, the 6 nucleotides deriving
from the random hexamer used for priming, and the last nucleotide
of the read, yielding 54 nt reads.
Background model (BGM) DNA sequence data sets included the
human genome (UCSC build hg18; BGMhg) (Lander et al., 2001;
Fujita et al., 2010), the human mRNA transcriptome (representative
H-Invitational transcripts, 43,159 records; BGMht) (Imanishi et al.,
2004), a collection of sequenced human VDJ recombination
products (Homo sapiens entries from IMGT release 201028-6
67,611 records; BGMvdj) (Lefranc, 2001), the Illumina paired-end
adapter sequences ligated to one another (BGMad), and an in vitro-
transcribed Xenopus EF1a message that contaminated Dataset A and
was reconstructed from that data (Supplementary File S1 online;
BGMef1a). Matches to BGMhg, BGMht, and BGMef1a of 480%
sequence identity across the entire read length were sought using
BLAT (-minIdentity¼ 80 -noTrimA) (Kent, 2002), and matches to
those data sets plus BGMvdj and BGMad were sought using Blastn
(default settings) (Altschul et al., 1990). Matching sequences and
their paired ends were filtered from the query pool, leaving the
‘‘host-filtered’’ read counts shown in Supplementary Table S2
online. Barcode AGG from Dataset A was excluded from further
analysis because of the majority of reads mapping to the BGMef1a
contaminating sequence (not shown). Low-complexity sequences
were defined as those generating o30 new additions to the string
table during the Lempel–Ziv–Welch compression (Welch, 1984) and
were removed, leaving the ‘‘complexity-filtered’’ read counts shown
in Supplementary Table S2 online.
Matches to the remaining reads were sought in a database of all
complete viral genome sequences in Genbank (3,525 records; 72
million nucleotides; downloaded on 18 January 2010; GIs listed in
Supplementary File S3 online) (Benson et al., 2009) using tBlastx (–e
1e–3). Read counts were allocated to the viral genome record with
the highest alignment bitscore. In the case of a tie, the read count
was initially distributed evenly to all records with equal bitscore
matches, and then re-assigned to whichever record(s) had the
greatest total read count for the given data set. ‘‘HPV-matching’’ read
counts for each sample are shown in Supplementary Table S2 online.
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